AI Agent Operational Lift for Psom Executive Vice Dean & Chief Scientific Officer in Philadelphia, Pennsylvania

What Penn Medicine's EVP/CSO Office Does

The Office of the Executive Vice Dean and Chief Scientific Officer at Penn Medicine is the strategic nerve center for research across one of the nation's top academic medical centers. It does not conduct experiments directly but sets the vision, allocates resources, oversees core research facilities, ensures regulatory compliance, and fosters interdisciplinary collaboration to advance biomedical science. The office manages a vast portfolio spanning basic, translational, and clinical research, supporting thousands of principal investigators and staff. Its mission is to maintain Penn's competitive edge in securing funding, publishing high-impact science, and translating discoveries into patient care.

Why AI Matters at This Scale

For a research enterprise of this magnitude (5,001-10,000 employees), manual oversight and decision-making are increasingly inefficient. The volume and complexity of data—from genomic sequences and medical images to grant texts and equipment logs—far exceed human capacity to synthesize. AI is not a luxury but a necessity to maintain leadership. It offers the only viable path to uncovering hidden patterns in data, optimizing multi-million-dollar resource allocation, and accelerating the entire research lifecycle from idea to publication and application. At this institutional scale, even marginal AI-driven improvements in grant success rates, trial recruitment speed, or operational efficiency can translate into tens of millions in additional research revenue and years of accelerated discovery.

Three Concrete AI Opportunities with ROI Framing

1. AI-Powered Grant Strategy & Development: By analyzing thousands of past successful grants from NIH and other funders, natural language processing models can identify funding trends, suggest optimal study sections, and provide feedback on proposal drafts. For an institution submitting thousands of proposals annually, a conservatively estimated 2-5% increase in success rates could yield $20-$50 million in additional annual direct research funding, delivering an immense ROI against the cost of AI software and specialist support.

2. Intelligent Clinical Trial Matching: Machine learning models applied to de-identified electronic health records can continuously screen patient populations for dozens of active clinical trials simultaneously. This reduces average patient recruitment time—a major trial cost and delay factor—by an estimated 30-50%. Faster recruitment means trials conclude sooner, getting therapies to market faster and reducing per-trial operational costs, which can run into the millions.

3. Predictive Analytics for Core Facility Management: The office oversees shared, expensive core facilities (e.g., sequencers, microscopes). AI-driven predictive maintenance on this equipment and demand forecasting for supplies can reduce unexpected downtime by ~25% and lower inventory costs by ~15%. This directly improves researcher productivity and reallocates hundreds of thousands of dollars annually from reactive repairs to proactive research investments.

Deployment Risks Specific to This Size Band

Implementing AI in a large, decentralized academic environment presents unique risks. Data Silos and Governance: Research data is fragmented across departments and labs, often in incompatible formats. Establishing unified data governance and access protocols is a massive, politically sensitive undertaking. Talent Retention: While talent exists internally, the institution competes with deep-pocketed tech and biotech firms for AI experts, risking a "brain drain." Change Management: Rolling out new AI tools to thousands of independent-minded researchers and administrators requires a carefully orchestrated change management strategy to overcome skepticism and ensure adoption. Regulatory and Ethical Scrutiny: AI models used in research, especially involving patient data, face intense scrutiny from IRBs, privacy boards, and funders, potentially slowing deployment and increasing compliance costs.